Td Vaccine Allocation Update

Ohio Department of Health

Vaccines for Children (VFC) Provider:

Historically, two tetanus and diphtheria (Td) vaccine products have been available for ordering through the VFC Program:

  • TdVaxTM, manufactured by MassBiologics
  • Tenivac®, manufactured by Sanofi

MassBiologics has discontinued production of TdVaxTM, and the existing supply is expected to last through June 2024. In response, Sanofi is taking steps to augment their available U.S. supply of Tenivac®. Despite these efforts, it’s anticipated that the supply of Td vaccine in the U.S. market will be constrained during 2024.

As a result, effective immediately, the Centers for Disease Control and Prevention (CDC) have established monthly allocations to help manage the remaining doses of TdVaxTM and the gap in Td vaccine supply for all  Td vaccine presentations available through the VFC program.  Please note that the mix of products available through the VFC Program will change over time and eventually will only include presentations of Sanofi’s Tenivac® product.

To manage the monthly allocation of Td vaccines, the Ohio Department of Health (ODH) VFC Program is implementing a provider order maximum of 10 doses total for all presentation of Td vaccine.  Providers will be able to place more frequent or monthly orders for VFC supplied Td vaccine as needed.

Due to the small monthly allocation, it is possible that a provider request/order for Td may be denied due to product unavailability. If this occurs, the ODH VFC Program will communicate with providers via email and other alternatives. 
Tdap vaccine, which is an alternative to Td vaccine in most circumstances, is available without supply constraints currently. The limited supply of Td vaccine needs to be preserved for those with a contraindication to receiving pertussis-containing vaccines. To assist vaccination providers, CDC  has developed the specific clinical guidance, which will remain in place until the period of temporary ordering controls for Td vaccine ends.